Cyanotech Corporation (Nasdaq Capital Market: CYAN), a world leader in
microalgae-based, high-value nutrition and health products, today
announced financial results for the third quarter and first nine months
of fiscal year 2012, ended December 31, 2011.
Third Quarter 2012
For the third quarter of fiscal 2012 compared to the third quarter of
fiscal 2011, revenues were $6,706,000 compared to $3,919,000. Gross
profit was $2,827,000, with gross profit margin of 42%, compared to
gross profit of $1,232,000 and gross profit margin of 31%. Net income
was $1,113,000 or $0.20 per diluted share, compared to net income of
$10,000 or $0.00 per diluted share.
Nine Months 2012
For the first nine months of fiscal 2012 compared to the first nine
months of fiscal 2011, revenues were $18,645,000 compared to
$11,609,000. Gross profit was $7,721,000, with gross profit margin of
41%, compared to gross profit of $4,543,000 and gross profit margin of
39%. Net income was $2,473,000 or $0.45 per diluted share, compared to
net income of $935,000 or $0.17 per diluted share.
Trailing 12 Months
For the trailing 12 months ended December 31, 2011, compared to the
trailing 12 months ended December 31, 2010, revenues were $23,863,000
compared to revenues of $15,423,000. Gross profit was $9,519,000, with
gross profit margin of 39.9%, compared to gross profit of $5,931,000 and
gross profit margin of 38.5%. Net income was $3,268,000 or $0.60 per
diluted share, including a non-cash tax benefit of $552,000 due to a
reduction in the deferred tax valuation allowance and recording of a net
deferred tax asset in the fourth quarter of fiscal 2011, compared to
$709,000, or $0.13 per diluted share. Income before income tax was
$2,771,000 compared to $715,000.
Commenting on the third quarter results, Brent Bailey, President and
CEO, said “We continued to make progress on key measures in the third
quarter compared to the third quarter of fiscal 2011:
-
Net sales reached a record level for the fourth consecutive quarter at
$6,706,000 (+$2,787,000 and +71%)
-
Gross margin increased to 42.2% (+10.8 pts.)
-
Net Income grew to $1,113,000 (+$1,103,000)
-
Cash increased to $4,190,000 (+$3,461,000 and +475%)
-
Inventory declined to $3,556,000 (-$800,000 and -18%)
“In addition, our Nutrex-branded sales grew +74% largely driven by the
mainland US natural products distribution channel.”
For the third quarter of fiscal 2012, Spirulina sales accounted for 31%
of total revenues and natural Astaxanthin sales for 69%. International
sales were 29% of total sales.
Mr. Bailey noted, “Abundant inventory coming out of last winter, plus
eight consecutive monthly astaxanthin production records, allowed us to
fully capitalize on the strong growth in spirulina and the exceptional
growth in astaxanthin resulting in four consecutive record net sales
quarters. While demand continues to grow, our production generally
declines during the winter months largely due to less sunlight. Going
forward, our astaxanthin capacity will increase by 33% in the spring as
we bring new ponds on line in April.”
About Cyanotech — Cyanotech Corporation, a world leader in
microalgae technology, produces BioAstin® Natural Astaxanthin and
Hawaiian Spirulina Pacifica®—all natural, functional nutrients
that leverage our experience and reputation for quality, building
nutritional brands which promote health and well-being. Cyanotech's
Spirulina products offer complete nutrition, and augment energy and
immune response. They are FDA-reviewed and accepted as Generally
Recognized as Safe (GRAS) for use in food products. BioAstin's superior
antioxidant activity and ability to support and maintain a natural
anti-inflammatory response enhance skin, muscle and joint health. All
Cyanotech products are produced from microalgae grown at its 90-acre
facility in Kona, Hawaii using patented and proprietary technology.
Cyanotech distributes to nutritional supplement, nutraceutical and
cosmeceutical manufacturers and marketers in more than 54 countries
worldwide. Cyanotech was the first microalgae company in the
world to obtain quality management standards ISO 9001:2000 certification
and is GMP-certified by the Natural Products AssociationTM.
Visit
for more information.
“Safe Harbor” Statement under the U.S. Private Securities Litigation
Reform Act of 1995 Besides statements of present fact and historical
fact, this press release may contain forward-looking statements.
Forward-looking statements relate to the future and are subject to
inherent uncertainties, risks and changes in circumstances that are
difficult to predict. Our actual results may differ materially from
those contemplated by forward-looking statements. We caution against
relying on forward-looking statements. Important factors that could
change actual, future results include: changes in sales levels to our
largest customers, weather patterns in Hawaii, production problems,
risks associated with new products, foreign exchange fluctuations, and
availability of financing, as well as national and global political,
economic, business, competitive, market and regulatory conditions. Other
factors are more fully detailed in the Company’s recent Form 10-Q and
annual Form 10-K filings with the Securities and Exchange Commission.
(Financial Tables Follow: The following tables do not contain
footnotes or other information contained in the Company’s Form 10-Q for
the period ended December 31, 2011. As such the following Financial
Tables are provided only as a guide and other factors are more fully
detailed in the Company’s Form 10-Q and annual Form 10-K filings with
the Securities and Exchange Commission.)
|
|
CYANOTECH CORPORATION AND SUBSIDIARIES |
CONDENSED CONSOLIDATED BALANCE SHEETS |
|
|
(Dollars in thousands except par value and number of shares)
|
(Unaudited)
|
|
|
|
|
|
| December 31, 2011 | |
|
|
| March 31, 2011 | |
|
ASSETS
| | | | | | | | | | |
|
Current assets:
| | | | | | | | | | |
|
Cash and cash equivalents
| | | |
$
|
4,190
| | | | |
$
|
2,062
| |
Accounts receivable, net of allowance for doubtful accounts of $52
at December 31, 2011 and $58 at March 31, 2011
| | | |
2,855
| | | | |
2,641
| |
|
Inventories, net
| | | |
3,556
| | | | |
3,627
| |
|
Deferred tax assets
| | | |
17
| | | | |
17
| |
|
Prepaid expenses and other assets
| | | |
374
| | | | |
134
| |
|
Total current assets
| | | |
10,992
| | | | |
8,481
| |
| | | | | | | | | |
|
|
Equipment and leasehold improvements, net
| | | |
5,416
| | | | |
4,557
| |
|
Deferred tax assets
| | | |
535
| | | | |
535
| |
|
Other assets
| | | |
291
| | | | |
287
| |
|
Total assets
| | | |
$
|
17,234
| | | | |
$
|
13,860
| |
| | | | | | | | | |
|
|
LIABILITIES AND STOCKHOLDERS’ EQUITY
| | | | | | | | | | |
|
Current liabilities:
| | | | | | | | | | |
|
Current maturities of long-term debt
| | | |
$
|
234
| | | | |
$
|
204
| |
|
Customer deposits
| | | |
39
| | | | |
115
| |
|
Accounts payable
| | | |
1,194
| | | | |
1,054
| |
|
Accrued expenses
| | | |
1,343
| | | | |
823
| |
|
Total current liabilities
| | | |
2,810
| | | | |
2,196
| |
| | | | | | | | | |
|
|
Long-term debt, excluding current maturities
| | | |
457
| | | | |
553
| |
|
Total liabilities
| | | |
3,267
| | | | |
2,749
| |
| | | | | | | | | |
|
|
Commitments and contingencies
| | | | | | | | | | |
| | | | | | | | | |
|
|
Stockholders’ equity:
| | | | | | | | | | |
Common stock of $0.02 par value, shares authorized 7,500,000;
5,434,598 shares issued and outstanding at December 31, 2011
and 5,391,968 shares at March 31, 2011
| | | |
109
| | | | |
108
| |
|
Additional paid-in capital
| | | |
28,185
| | | | |
27,803
| |
|
Accumulated deficit
| | | |
(14,327
|
)
| | | |
(16,800
|
)
|
|
Total stockholders’ equity
| | | |
13,967
| | | | |
11,111
| |
| | | | | | | | | |
|
|
Total liabilities and stockholders’ equity
| | | |
$
|
17,234
| | | | |
$
|
13,860
| |
| | | | | | | | | | | |
|
|
|
CYANOTECH CORPORATION AND SUBSIDIARIES |
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS |
|
|
(Dollars in thousands, except per share amounts)
|
(Unaudited)
|
|
|
|
|
|
| Three Months Ended December 31, | |
|
|
| Nine Months Ended December 31, | |
| | | | 2011 | |
|
|
| 2010 | | | | | 2011 | |
|
|
| 2010 | |
| | | | | | | | | | | | | | | | | | | |
|
|
NET SALES
| | | |
$
|
6,706
| | | | |
$
|
3,919
| | | | |
$
|
18,645
| | | | |
$
|
11,609
| |
|
COST OF SALES
| | | |
3,879
| | | | |
2,687
| | | | |
10,924
| | | | |
7,066
| |
|
Gross profit
| | | |
2,827
| | | | |
1,232
| | | | |
7,721
| | | | |
4,543
| |
| | | | | | | | | | | | | | | | | | | |
|
|
OPERATING EXPENSES:
| | | | | | | | | | | | | | | | | | | | |
|
General and administrative
| | | |
955
| | | | |
630
| | | | |
3,019
| | | | |
2,036
| |
|
Sales and marketing
| | | |
631
| | | | |
502
| | | | |
1,808
| | | | |
1,278
| |
|
Research and development
| | | |
77
| | | | |
83
| | | | |
237
| | | | |
229
| |
|
Loss on disposal of equipment and leasehold improvements
| | | |
1
| | | | |
—
| | | | |
65
| | | | |
—
| |
|
Total operating expenses
| | | |
1,664
| | | | |
1,215
| | | | |
5,129
| | | | |
3,543
| |
| | | | | | | | | | | | | | | | | | | |
|
|
Income from operations
| | | |
1,163
| | | | |
17
| | | | |
2,592
| | | | |
1,000
| |
| | | | | | | | | | | | | | | | | | | |
|
|
Interest expense, net
| | | |
(14
|
)
| | | |
(16
|
)
| | | |
(38
|
)
| | | |
(54
|
)
|
| | | | | | | | | | | | | | | | | | | |
|
|
Income before provision for income taxes
| | | |
1,149
| | | | |
1
| | | | |
2,554
| | | | |
946
| |
| | | | | | | | | | | | | | | | | | | |
|
|
PROVISION FOR (BENEFIT FROM) INCOME TAXES
| | | |
36
| | | | |
(9
|
)
| | | |
81
| | | | |
11
| |
| | | | | | | | | | | | | | | | | | | |
|
|
NET INCOME
| | | |
$
|
1,113
| | | | |
$
|
10
| | | | |
$
|
2,473
| | | | |
$
|
935
| |
| | | | | | | | | | | | | | | | | | | |
|
|
NET INCOME PER SHARE:
| | | | | | | | | | | | | | | | | | | | |
|
Basic
| | | |
$
|
0.21
| | | | |
$
|
0.00
| | | | |
$
|
0.46
| | | | |
$
|
0.18
| |
|
Diluted
| | | |
$
|
0.20
| | | | |
$
|
0.00
| | | | |
$
|
0.45
| | | | |
$
|
0.17
| |
| | | | | | | | | | | | | | | | | | | |
|
|
SHARES USED IN CALCULATION OF NET INCOME PER SHARE:
| | | | | | | | | | | | | | | | | | | | |
|
Basic
| | | |
5,424
| | | | |
5,392
| | | | |
5,406
| | | | |
5,340
| |
|
Diluted
| | | |
5,571
| | | | |
5,423
| | | | |
5,490
| | | | |
5,366
| |
